Minireviews
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. May 14, 2022; 28(18): 1922-1933
Published online May 14, 2022. doi: 10.3748/wjg.v28.i18.1922
Novel drug delivery systems for inflammatory bowel disease
Farah Yasmin, Hala Najeeb, Shehryar Shaikh, Muhammad Hasanain, Unaiza Naeem, Abdul Moeed, Thoyaja Koritala, Syedadeel Hasan, Salim Surani
Farah Yasmin, Hala Najeeb, Muhammad Hasanain, Unaiza Naeem, Abdul Moeed, Department of Medicine, Dow University of Health Science, Karachi 74200, Pakistan
Shehryar Shaikh, Department of Medicine, Dow OJha University Hospital, Karachi 74200, Pakistan
Thoyaja Koritala, Department of Medicine, Mayo Clinic Health System, Mankato, MN 56001, United States.
Syedadeel Hasan, Department of Medicine, University of Louisville, Louisville, KY 40292, United States
Salim Surani, Department of Medicine, Texas A&M University, College Station, TX 77843, United States
Salim Surani, Department of Anesthesiology, Mayo Clinic, Rochester, MN 55901, United States
Author contributions: Yasmin F primarily drafted the work, Yasmin F, Najeeb H, Shaikh S, Hasanain M, Naeem U, Moeed A and Surani S contributed to the conception of this study; Najeeb H, Shaikh S, Hasanain M, Naeem U and Moeed A did the drafting of the work; Surani S critically revised the manuscript; Koritala T and Hassan SA did the literature search and reviewed the manuscript; Najeeb H, Shaikh S, Hasanain M, Naeem U, Moeed A and Surani S did the final approval, and agreed to the accuracy of the work.
Conflict-of-interest statement: None.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Salim Surani, FACP, FCCP, MD, MSc, Doctor, Professor, Department of Medicine, Texas A&M University, 400 Bizzell Street, College Station, TX 77843, United States. srsurani@hotmail.com
Received: November 13, 2021
Peer-review started: November 13, 2021
First decision: January 9, 2022
Revised: January 22, 2022
Accepted: March 26, 2022
Article in press: March 26, 2022
Published online: May 14, 2022
Core Tip

Core Tip: Current literature on novel drug delivery systems is extensive. However, limited content is available that focuses on the novel drug delivery strategies, focally the enteric-coated microneedles pills and biological drug delivery systems. In our review, we discuss multiple novel approaches comprehensively, after outlining the disease course in inflammatory bowel diseases (IBD) and how the conventional routes of drug administrations are deficient in addressing some aspects of disease treatment. We specify that novel carrier systems can be considered for targeting inflamed sites in IBD and discuss the implications of choosing such routes.